ARV regimen

DRUG4 trials

Sponsors

Hoffmann-La Roche, Gilead Sciences

Conditions

HIV InfectionsHIV-1 InfectionHIV-1-infection

Phase 1

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

CompletedNCT02858401

Gilead SciencesHIV-1 Infection

Start: 2015-01-29End: 2019-02-14Updated: 2020-02-21

Phase 2

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

CompletedNCT00445146

Gilead SciencesHIV Infections

Start: 2007-02-28End: 2015-03-31Updated: 2016-04-25

Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus

TerminatedNCT03472326

Gilead SciencesHIV-1-infection

Start: 2018-04-03End: 2019-12-09Updated: 2021-01-05

Phase 4

QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection

CompletedNCT00232908

Hoffmann-La RocheHIV Infections

Start: 2004-06-30End: 2005-10-31Updated: 2016-11-02

Related Papers

HIV rebound in HIV controllers is associated with a specific fecal microbiome profile

European Journal of Immunology2024-05-101 citations

Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus–1

Clinical Infectious Diseases2020-10-0672 citations